Sanofi broke ground on a new state-of-the-art insulin manufacturing facility at its BioCampus in Frankfurt, Germany. The new facility will bring a new generation of insulin production to one of Sanofi’s largest integrated research and manufacturing sites, strengthening Sanofi’s long-term ability to provide a reliable supply of insulin to millions of people living with diabetes around the world.
Prime Minister of the State of Hesse Boris Rhein and Mayor of Frankfurt Mike Josef joined Belén Garijo, Chief Executive Officer of Sanofi, Brendan O’Callaghan, Sanofi Executive Vice President, Manufacturing & Supply and Chairman of the Supervisory Board of Sanofi in Germany, and Madeleine Roach, Country President of Sanofi in Germany, at today’s groundbreaking ceremony.
The new facility will be built on a 36,000-square-meter footprint at the Sanofi BioCampus in Frankfurt, equivalent to approximately five football fields. Designed to meet the highest standards of quality and automation, it will leverage advanced digital technologies and artificial intelligence across manufacturing and quality processes.
Full production of insulin active pharmaceutical ingredient is planned for 2032, once the facility is fully licensed. Building on more than a century of manufacturing expertise in Frankfurt, the facility will combine advanced manufacturing technologies, automation and digital capabilities. Once operational, it will be among the largest and most advanced insulin manufacturing facilities in Europe and an important part of Sanofi’s global insulin supply network.